1. Short title This Act may be cited as the Pediatric Cancer Drug Supply Act of 2024 . 2. Establishment of essential pediatric cancer drug marketplace stability pilot program (a) In general The Secretary shall carry out a pilot program under which the Secretary enters into agreements with manufacturers to purchase and maintain not less than a 6-month reserve supply, to be held by such manufacturers, of each covered pediatric cancer drug. (b) Pilot program (1) Preference for multiple manufacturers To the greatest extent practicable, the Secretary shall seek to enter into agreements described in subsection (a) with more than 1 manufacturer for each covered pediatric cancer drug. (2) Implementation goals To the greatest extent practicable, the Secretary shall implement the pilot program under this section in a manner that— (A) minimizes the impact on the marketplace for drugs included on the essential pediatric cancer drug list established under section 3; (B) increases domestic manufacturing capacity; (C) encourages competition in the marketplace; (D) assures that any covered pediatric cancer drugs that the Secretary distributes or orders to be distributed under section 4 are used to treat pediatric cancer patients